

Annual General Meeting Presentation

Judith Mitchell, Managing Director

May 5, 2021

NEXT SCIENCE[®]

AT A GLANCE



Currently the only company in the world solely dedicated to developing products that resolve biofilm based infections

3 products in the US human healthcare market

Additional regulatory approvals of CE Mark and TGA to support revenue growth through market access to Australia, UK, Germany, Netherlands, Nordic countries and France

New product XPERIENCE™ currently launching in the US. This is a new no rinse antimicrobial solution for use in Surgery and treatment rooms to prevent Surgical Site Infection, a total global addressable market of >\$15B pa

KEY STATISTICS



Treated over 150,000 patients



All Products are effective in removing key community acquired pathogens from any area they are used to treat (Skin, surgical cavities):


- MRSA (Golden Staph)
- COVID-19
- E.coli
- Pseudomonas



34 patents awarded (April 2021)


*Please refer to Next Science website for further details

US Hospitals Using X BIO Products



Represents ~10% of total Hospitals and Ambulatory Surgery Centres*

Patients treated to date with X BIO Products



2020 HIGHLIGHTS

- ✓ Returned revenue to growth in Q4 (Q4 2020 on Q4 2019 75% growth).
- ✓ 2 CE Marks awarded (BACTISURE™ and BLASTX®)
- ✓ 1st TGA approval (BACTISURE™) and Zimmer launched in Australia in Q4
- ✓ Patent portfolio increased to 34 patents
- ✓ Commissioned the direct Surgical Sales team and contracted a commissioned sales force of over 200 people in the US
- ✓ Capital raise of A\$15M successfully completed to fund the commercialisation of XPERIENCE™ in the US (1H 2021) and support the company's long term growth strategy

January – April 2021 HIGHLIGHTS

- ✓ Continuing momentum into 2021
- ✓ Launched XPerience No Rinse Antimicrobial Solution on April 27th, 2021
- ✓ Q1 Revenue \$2.2M (unaudited)
- ✓ Bactisure launched in Europe with Zimmer Biomet
- ✓ BlastX distribution transition back to Next Science – 1 April 2021

[illegible]

XPERIENCETM


No Rinse Antimicrobial Solution

Single step no rinse antimicrobial solution to be offered to address the global \$15B pa market of surgical site infection prevention

- ✓ 5+ hours of protection
- ✓ No rinse out required
- ✓ Non toxic
- ✓ Broad spectrum efficacy against bacteria, viruses and fungi
- ✓ No change to current surgical protocols
- ✓ Easy to use and adopt
- ✓ Creates significant cost savings for hospitals
- ✓ Inventory pre-ordered to meet initial sales
- ✓ Priced <US\$200 per 500ml bottle



Biofilm efficacy (test results from MSU)



Products remained in contact with the biofilm for times consistent with their intended uses.

The study was conducted across various materials and contact times. Standard deviations within data sets show high variability

Product Launched APRIL 27th , 2021

US Market

| Treatment Area | Millions of procedures |
|------------------------|------------------------|
| Orthopaedics* | 5.3 |
| Plastic Surgery* | 1.3 |
| Spine Surgery* | 1.0 |
| Emergency room injury* | 35.0 |
| Colorectal Surgery* | 0.6 |
| CMF Surgeries* | 1.0 |

Outside the US

| Treatment Area | Millions of procedures |
|-----------------------|------------------------------|
| Orthopaedics | 17.0 |
| Plastic Surgery | 10.0 |
| Spine Surgery | 5.2 |
| Emergency room injury | No consistent data available |
| Colorectal Surgery | 1.4 |
| CMF Surgeries | 3.5 |

*Clinical study sites identified, protocols and plans under development. Additional opportunities such as Cardiac procedures and surgeries and vascular surgeries will be part of wave two, along with field medical use in ambulances

| Indication PI | Product | Size | Status | Comment |
|--|------------|-------|---------------------------------|--|
| Surgical Site Infection in Colorectal surgery | XPERIENCE™ | 560 | IRB Review underway | Randomised Control study 3 sites |
| Compound Tibial Fracture Infection | XPERIENCE™ | 50 | Pilot study 1 site IRB approved | Sites – Dr C Harris Hughston Memorial Clinic Commenced Recruitment |
| Surgical Site Infection in Primary Joint Replacement in complex patients | XPERIENCE™ | 1,200 | IRB Submission underway | Dr Mont Principle Investigator Northwell Group (NY, Long Island, Baltimore) |
| Pre & Post use PCR sampling | XPERIENCE™ | 100 | IRB Submissions underway | Sites- Mayo Clinic (Dr Ledford), Northside Hospital (Dr Minter) |

Pathway for in hospital approval for use



NPR approvals range between 30 – 300 days depending on facility

NPR = New Product Request

BLASTX[®] Antimicrobial Wound Gel

Product Plan



BLASTX[™]
DISCOVER THE X FACTOR
Antimicrobial Wound Gel



Returning to Next Science from 1 April 2021 with strategies to expand market opportunities

- ✓ US Chronic Wound population 8.2M growing at 5.6% pa
- ✓ 2020 Channel
 - ✓ Outpatient Wound Clinics

Next steps 2021:
Launch in unserved markets:

- ✓ Acute Care Hospitals
- ✓ Home Health
- ✓ Long Term Acute Care



23 April 2019



21 May 2019



Healed: 23 May 2019

Results:

86% wound area reduction within 28 days of starting BLASTX[®] Antimicrobial Wound Gel

²

"I am again amazed how quickly BLASTX[®] healed this 2 year-old chronic wound."

- Karlene Wood, RN, WCC, CWS

BLASTX[®] is approved and can be offered for all wounds in all sites of treatment. Expanding BLASTX[®] distribution into new markets more than doubles the potential market.

- ✓ BLASTX[®] advances healing in all wound types:
 - ✓ Diabetic Foot Ulcers
 - ✓ Venous Leg Ulcers

Clinical evidence now available to expand into

- ✓ Pressure Ulcers
- ✓ Non healing Surgical wounds

Expanding into infection prevention significantly enhances addressable market opportunities

Prevention products in market

- Surgical Site Infection
- Prosthetic Joint Infection
- Acne

Treatment products in market

- Surgical Site Infection
- Prosthetic Joint Infection
- Acne and skin health
- Chronic Wounds

Products in development

- Chronic Middle Ear Infection
- Chronic Sinusitis

Research underway

- Skin health
- Lung infections including pneumor and cystic fibrosis
- Dental implants, peridontitis
- Catheter infections
- Implant infections

Potential for future research

- Endocarditis
- Kidney stones
- Biliary tract infection
- Urinary tract infection
- Vaginosis
- Osteomyelitis

CHRONIC BACTERIAL INFECTIONS: MEDICAL BIOFILMS

Device-related Infections:

- Ventricular derivations
- Contact lenses
- Mouthwash
- Endotracheal tubes
- Vascular central catheters
- Tissue fillers, breast implants
- Peripheral vascular catheters
- Prosthetic cardiac valves, pacemakers and vascular grafts
- Urinary catheters
- Orthopedic implants and prosthetic joints

Tissue Infections:

- Acne
- Chronic otitis media, chronic sinusitis
- Chronic tonsillitis dental plaque, chronic laryngitis
- Endocarditis
- Lung infection in cystic fibrosis
- Kidney stones
- Biliary tract infections
- Urinary tract infections
- Vaginosis
- Osteomyelitis
- Surgical site infections
- Chronic wounds

The 2021 priority is the commercial success of XPERIENCE™

- Q1 Revenue USD\$2.2M (unaudited)
- **XPERIENCE™ Launched April 27th, 2021. Sales commenced, product shipped, surgeries completed**
- BACTISURE™ Wound Lavage launched in Europe Q1 2021
- BLASTX® returned to Next Science 1 April 2021
- TORRENTX™ launching 2H 2021

**Strengthening distribution, launching new products,
entering new markets and growing revenue**

Disclaimer

This presentation has been prepared by Next Science Limited (**Company**) and is provided for general information purposes only. It is not a product disclosure statement, pathfinder document or any other disclosure document for the purposes of the *Corporations Act 2001* (Cth) and has not been, and is not required to be, lodged with the Australian Securities and Investments Commission (**ASIC**). It should not be relied upon by the recipient in considering the merits of the Company or the acquisition of shares in the Company. This presentation should not be considered an offer or an invitation to acquire or sell, or a solicitation to invest in or refrain from investing in, new shares in the Company or any other financial products.

This document has been prepared based on information available as at the date of this presentation. It contains selected summary information and does not purport to be all-inclusive, comprehensive or to contain all of the information that may be relevant or which a prospective investor may require in evaluations for a possible investment in the Company. It should be read in conjunction with the Company's periodic and continuous disclosure announcements which are available at www.nextscience.com and www.asx.com.au. The recipient acknowledges that circumstances may change and that this presentation may become outdated as a result. This presentation and the information in it are subject to change without notice. The Company is not obliged to update this presentation.

The information contained in this presentation does not constitute investment, legal, tax, accounting or financial product advice nor any recommendation to acquire securities in the Company. This presentation has been prepared without taking account of any person's individual investment objectives, financial situation or particular needs. Before making an investment decision, the recipient should consider its own financial situation, objectives and needs, and conduct its own independent investigation and assessment of the contents of this presentation, including obtaining investment, legal, tax, accounting and such other advice as it considers necessary or appropriate. Any references to or explanations of legislation, regulatory issues, benefits or any other legal commentary (if any) are indicative only, do not summarise all relevant issues and are not intended to be a full explanation of a particular matter. The information in this presentation has been obtained from and based on sources believed by the Company to be reliable. Past performance is not an indication of future performance.

This presentation may contain forward-looking statements, guidance, forecasts, estimates, prospects, projections or statements in relation to future matters that may involve risks or uncertainties and may involve significant items of subjective judgement and assumptions of future events that may or may not eventuate (**Forward Statements**). Forward Statements can generally be identified by the use of forward looking words such as "anticipate", "estimates", "will", "should", "could", "may", "expects", "plans", "forecast", "target" or similar expressions. Forward Statements including indications, guidance or outlook on future revenues, distributions or financial position and performance or return or growth in underlying investments are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. No independent third party has reviewed the reasonableness of any such statements or assumptions. None of the Company, its related bodies corporate and their respective officers, directors, employees, advisers, partners, affiliates and agents (together, the **Next Science Parties**) represent or warrant that such Forward Statements will be achieved or will prove to be correct or gives any warranty, express or implied, as to the accuracy, completeness, likelihood of achievement or reasonableness of any Forward Statement contained in this presentation. Except as required by law or regulation, the Company assumes no obligation to release updates or revisions to Forward Statements to reflect any changes. Recipients should form their own views as to these matters and any assumptions on which any of the Forward Statements are based and not place reliance on such statements.

All dollar values are in USD unless stated otherwise.

An investment in Company shares is subject to investment and other known and unknown risks, some of which are beyond the control of the Company, including factors and risks specific to the industry in which Next Science operates as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets. The Company does not guarantee any particular rate of return on its performance nor does it guarantee any particular tax treatment. Prospective investors should make their own enquiries and investigations regarding all information in this presentation, including the assumptions, uncertainties and contingencies which may affect future operations of the Company and the impact that different future outcomes may have on the Company.

The distribution of this presentation to persons or in jurisdictions outside Australia may be restricted by law and any person into whose possession this document comes should seek advice on and observe those restrictions. Any failure to comply with such restrictions may violate applicable securities law.

No party other than the Company has authorised, permitted or caused the issue, submission, dispatch or provision of this presentation, or takes any responsibility for, or makes or purports to make any statement, representation or undertaking in this presentation and there is no statement in this presentation that is based on any statement by any other party. No person, either as a director or partner of, or in the employment of, the Company has any authority to make, imply, or give any representation or warranty whatsoever in relation to the information contained in this presentation. None of the Next Science Parties take any responsibility for any information in this presentation or any action taken by you on the basis of such information. To the maximum extent permitted by law, the Next Science Parties:

exclude and disclaim all liability, including (without limitation) any liability for fraud or negligence, for any expenses, losses, damages or costs incurred either as a result of the information in this presentation being inaccurate or incomplete in any way for any reason, or otherwise arising in connection with this presentation; and make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of information in this presentation.

Authorised by the Next Science Board

May 4, 2021

investorqueries@nextscience.com | +61 2 8607 5125 | NextScience.com

Suite 1902 Tower A 821 Pacific Highway Chatswood NSW 2067

NEXT SCIENCE[®]

Additional biofilm education can be found at: biofilm.healthcare